Summary DNA topoisomerase I (topo I) is the principle target for camptothecin and its derivatives such as SN38. Levels of topo I expression vary widely between and within tumour types and the basis for this is poorly understood. We have used fluorescence in situ hybridisation to detect the topo I locus in a panel of breast and colon cancer cell lines. This approach has identified a range of topo I gene copies from 1 to 6 between the cell lines as a result of DNA amplification, polysomy and isochromosome formation. Topo I gene copy number was highly correlated with topo I expression, (r, = 0.92), and inversely correlated to sensitivity to a 1 h exposure to SN38 (r, = -0.904). This illustrates the significant impact of altered topo I gene copy number on intrinsic drug sensitivity and influences potential mechanisms for acquisition of drug resistance.
DNA topoisomerase I (topo I) is a nuclear enzyme that catalyses the breakage and rejoining of DNA, allowing the strands to pass through one another. In normal cells, topo I activity is probably required for gene transcription and possibly for DNA synthesis and replication (Slichenmyer et al., 1993) . The topo I inhibitors are an exciting new class of antineoplastic agents with activity in patients with refractory solid tumour malignancies (reviewed in Potmesil, 1994) . Human cancer cell lines with acquired resistance to topo I inhibitors in vitro have demonstrated point mutations in the topo I gene or down-regulation of topo I expression (reviewed in Pommier et al., 1994) . Whereas these mechanisms of resistance may have clinical relevance in long-term treatment with topo I inhibitors, they provide little insight into the mechanisms for intrinsic resistance to topo I inhibition. One postulated source of altered senstivity to topo I inhibitors is variable topo I expression. A wide range of topo I protein expression and catalytic activity has been observed in human tumours, with significant variation within specific tumour types (McLeod et al., 1994; Husain et al., 1994) . The basis for variable expression of topo I has not been elucidated. Genetic alterations in the region of the topo I locus on chromosome 20q have been reported in breast cancer biopsies and cell lines (Devilee et al., 1991; Keith et al., 1993; Tanner et al., 1994; Kallioniemi et al., 1994) , but there is relatively little information on direct changes to the topo I locus, (Keith et al., 1993) . Therefore, we examined four breast cancer cell lines available in our laboratory for alterations at the topo I locus in an attempt to generate valuable well-characterised cell line models for the study of drug sensitivity. In addition, the colon cancer cell line HT29 was included in the study as it is routinely used in a number of laboratories for topoisomerase studies, (Tanizawa et al., 1994) . In this study we demonstrate altered topo I gene copy number in human breast and colon carcinoma cell lines and establish correlations between copy number, protein expression and intrinsic sensitivity to topo I inhibition, thereby providing evidence for alterations in topo I gene copy number as a mechanism for intrinsic resistance to topo I-directed therapy.
Materials and methods Cell lines and chemicals
Four human breast carcinoma cell lines (MCF-7, ZR75-1, MB MDA231, MB MDA436) and one human colon carcinoma cell line (HT29) were obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained as previously described (McLeod et al., 1994) . All chemicals were obtained from Sigma (Dorset, UK) and were of the highest available grade. The topo I inhibitor SN38 was a kind gift from Dr J-F Riou, Rh6ne-Poulenc Rorer Bellon (Neuilly sur Seine, France). SN38 is the active metabolite of CPT 1, a potent analogue of camptothecin, and has a high level of specificity for inhibition of topo I (Potmesil, 1994) .
Cytotoxicity assay
The cytotoxic activity of SN38 was determined by the MTT assay (Plumb et al., 1989) . Multiwell plates were seeded at 1 x 103 cells per well and maintained for 48 h. Cells were then exposed to drug at 0.000128 -10jIM for 1 to 24 h. Cells were then maintained in drug-free medium for 72 h. Reduction of tetrazolium dye was determined after addition of MTT to each well for 4 h, solubilised in dimethyl sulphoxide (DMSO) and glycine buffer and measured at 570 nm. The concentration lethal to 50% of cells (IC50) Fluorescence in situ hybridisation The topo I probe used for fluorescence in situ hybridisation (FISH), was a phage clone designated TP3.6, (kindly provided by Dr N Kunze), which contains genomic DNA encompassing the third exon of the functional topo I gene, (Kunze et al., 1991) . The sequences present in this clone are not present in the two topo I pseudogenes and do not crosshybridise with them. Probe labelling, in situ hybridisation and probe detection are as previously described, (Coutts et al., 1993; Murphy et al., 1995) , using the Hybaid Omnislide system (Hybaid Ltd, Teddington, UK). The topo I probe was localised by fractional length measurements, Flpter, where the Flpter is the distance from the probe location to the end of the short arm of chromosome 20 divided by the total length of the chromosome, (Lichter et al., 1990; Mascio et al., 1995; Sakamoto et al., 1995) . Analysis of digitised images for Flpter measurements was carried out using IPLab Spectrum software with SmartCapture extension from Digital Scientific (Cambridge, UK). Images were processed using edge enhancement algorithms (Comos Software, Bio-Rad) to aid definition of chromosome boundaries and hybridisation sites and length measurements carried out using IPLab spectrum. In addition, GraphPolygon was used to produce an intensity plot along the profile of the chromosome where the width of the chromosome was determined in pixels and the average intensity over the width plotted. Thus, a visual representation of the hybridisation site relative to the chromosome profile is generated, (see Figure lb) . The unit of measurement is 1 pixel.
Statistics
The correlation between gene copy number, topo I protein content, and cytotoxicity was assessed by the Spearman rank correlation test.
Results
Detection and mapping of the topo I locus Topo I sequences were detected by FISH using a phage clone designated TP3.6, (Kunze et al., 1991) . Figure la shows an example of detection of topo I sequences in normal lymphocyte chromosomes by FISH. Hybridisation efficiency for TP3.6 on lymphocytes is 85% when efficiency is defined as the percentage of metaphase spreads with both chromosome 20 homologues and both chromatids labelled. Forty metaphase spreads were analysed. Juan et al. (1988) and Kunze et al. (1989) , have previously mapped the topo I locus to chromosome bands 20qll.2-ql3.2 by isotopic in situ hybridisation. With the rapid progress in molecular cytogenetics and the use of FISH to assemble physical maps, standard ideograms are often unsuitable for the description of probe localisation. An appealing and robust approach to mapping probe localisation by FISH is to define the map position of the hybridisation signal as the fractional length along the (Figure 2) . A 2.6-fold range in topo I protein levels was observed in nuclear extracts (Table I) Figure 3b ). This relationship was not apparent after a 24 h drug exposure, (Table II) . This study shows a significant relationship between topo I copy number, topo I protein expression, and cellular sensitivity to topo I inhibition, thus demonstrating for the first time the importance of genetic background as a determinant of intrinsic resistance to topo I-targeting agents. However, it is unlikely that the observed genetic changes at the topo I locus are initial driving oncogenic events during tumour development. Rather, gene dosage changes at the topo I locus, including gene amplification, isochromosome formation and polysomy, are most likely due to selection for alterations to chromosome 20 at for example an oncogene in the proximity of topo I. This situation has been shown to occur for the topo IIcx locus on chromosome 17q, which can be co-amplified along with the erbB2 oncogene in a proportion of breast cancers resulting in high levels of topo Ilo expression, (Coutts et al., 1993; Keith et al., 1993; Murphy et al., 1995) . Both allelic imbalances and gene amplification have been detected on chromosome 20 in breast cancer, (Devilee et al., 1991; Keith et al., 1993; Kallioniemi et al., 1994; Tanner et al., 1994) . Indeed, a high proportion of primary breast cancers and cell lines show amplification of sequences originating close to the topo I locus on chromosome 20 (Tanner et al., 1994; Kallioniemi et al., 1994 ). Tanner et al. (1994 have shown the MCF7 cell line to have such an amplicon and so provide a representative cell line model for the in vivo situation. The three copies of topo I clustering to a region of an MCF7 chromosome ( Figure If) are probably included within the amplicon described by Tanner et al. (1994) , albeit at a lower copy number than other markers closer to the selective locus. However, the present study emphasises that fortuitious amplification of the topo I locus in breast cancer may occur and could lead to high levels of target for enzyme inhibition. Thus, in conjunction with other mechanisms operating to deviate the number of topo I gene copies from normal, the intrinsic sensitivity of tumours to topo I-inhibitory drugs may in part be controlled at the genetic level.
The current results also have implications for both developmental mechanisms of resistance to topo I inhibition and strategies for enhancing drug sensitivity. These studies emphasise the need for genetic characterisation before creation of resistant cell lines. If only one gene copy is present at initiation of study, as was the case for MB MDA436, selection for down-regulation of topo I expression may be difficult owing to the cells normal requirement for topo I activity, (Lee et al., 1993) . Indeed, the cell line may display some intrinsic resistance and so further increase in resistance may only be possible through acquired gene mutation affecting drug interaction, but not normal catalytic activity. It has been shown in primary breast cancer biopsies that allele loss at the topo I locus can occur, suggesting that tumours can pass through a stage at which they have only one copy of the topo I locus (Keith et al., 1993) . Cell lines such as MB MDA436 may therefore fulfil a role as a model for tumours with only one copy of topo I undergoing exposure to a topo I inhibitor.
Cell lines with multiple copies of topo I at the outset of selection for resistance, such as MCF7 in this study, are unlikely to mutate all gene copies as this may require up to Topo gene copy number Figure 3 Graphical representation of the relationship between, (a) topo I gene copy number and topo I expression, (b) topo I gene copy number and cellular sensitivity to the topo I enzymeinteractive drug, SN38, (log IC50, 1 h exposure). , 1986) . The data presented in Table I suggest that if a tumour cell population consisted of subclones with variable numbers of topo I genes, exposure to a topo I inhibitor such as SN38 may in fact select for the cells with intrinsic resistance like MB MDA436. Finally, although the intrinsic resistance to a 1 h exposure to topo I inhibition is closely associated with topo I gene copy number, it is of interest to note that this relationship is less apparent after a 24 h drug exposure (Table II) . This possibly suggests that a threshold number of damaging events is reached, or other molecular determinants, such as stimulation of a functional apoptotic pathway, become important with prolonged drug exposure. However, the quantity of cellular target may still have some influence on sensitivity after 24 drug exposure when present at high levels, as MCF7 cells had six copies of the topo I gene and an IC50 value 2 logs lower than the other cell lines (Table I) . Therefore strategies designed to optimise and enhance the use of topo I inhibitors clearly require a greater understanding of the relationship between the genotype and phenotype of drug resistance.
